Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Patients with more severe damage caused by systemic lupus erythematosus spend four times as much on healthcare than those with the lowest levels of lupus damage, Canadian researchers said ... Read more
A tool for measuring patient-reported outcomes, called PROMIS-29, performed rather well in a study attempting to validate the approach in patients with systemic lupus erythematosus and other rheumatic conditions. ... Read more
Patients with systemic lupus erythematosus have an increased risk for cardiovascular and metabolic diseases — a risk that they share with patients who have other chronic inflammatory conditions, according ... Read more
Neovacs’ Phase 2b clinical trial of an interferon immunotherapy for lupus is going according to plan, the company announced after an independent review board declined to recommend modifications to the ... Read more
An ongoing online survey to examine the distribution of blood types among lupus patients could provide important information about why people develop the disease, researchers say. The survey is a collaboration ... Read more
Neuropsychiatric symptoms in people with systemic lupus erythematosus may be caused by increased levels of the inflammatory molecule interferon-alpha in their brains, according to a study published in the journal Nature. ... Read more
A Phase 2a trial (NCT02185040) evaluating Celgene International‘s CC-220 in systemic lupus erythematosus (SLE) reports promising results, according to data presented at the Annual European Congress of Rheumatology (EULAR) 2017, held June ... Read more